296 related articles for article (PubMed ID: 27377794)
1. The pan-Kv7 (KCNQ) Channel Opener Retigabine Inhibits Striatal Excitability by Direct Action on Striatal Neurons In Vivo.
Hansen HH; Weikop P; Mikkelsen MD; Rode F; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2017 Jan; 120(1):46-51. PubMed ID: 27377794
[TBL] [Abstract][Full Text] [Related]
2. The KCNQ channel activator retigabine blocks haloperidol-induced c-Fos expression in the striatum of the rat.
Mikkelsen JD
Neurosci Lett; 2004 May; 362(3):240-3. PubMed ID: 15158023
[TBL] [Abstract][Full Text] [Related]
3. The KCNQ channel opener retigabine inhibits the activity of mesencephalic dopaminergic systems of the rat.
Hansen HH; Ebbesen C; Mathiesen C; Weikop P; Rønn LC; Waroux O; Scuvée-Moreau J; Seutin V; Mikkelsen JD
J Pharmacol Exp Ther; 2006 Sep; 318(3):1006-19. PubMed ID: 16775195
[TBL] [Abstract][Full Text] [Related]
4. The neuronal KCNQ channel opener retigabine inhibits locomotor activity and reduces forebrain excitatory responses to the psychostimulants cocaine, methylphenidate and phencyclidine.
Hansen HH; Andreasen JT; Weikop P; Mirza N; Scheel-Krüger J; Mikkelsen JD
Eur J Pharmacol; 2007 Sep; 570(1-3):77-88. PubMed ID: 17628530
[TBL] [Abstract][Full Text] [Related]
5. Activation of KCNQ channels located on the skeletal muscle membrane by retigabine and its influence on the maximal muscle force in rat muscle strips.
Zagorchev P; Apostolova E; Kokova V; Peychev L
Naunyn Schmiedebergs Arch Pharmacol; 2016 Apr; 389(4):439-46. PubMed ID: 26815201
[TBL] [Abstract][Full Text] [Related]
6. Kv7/KCNQ/M-channels in rat glutamatergic hippocampal axons and their role in regulation of excitability and transmitter release.
Vervaeke K; Gu N; Agdestein C; Hu H; Storm JF
J Physiol; 2006 Oct; 576(Pt 1):235-56. PubMed ID: 16840518
[TBL] [Abstract][Full Text] [Related]
7. Antipsychotic-like effect of retigabine [N-(2-Amino-4-(fluorobenzylamino)-phenyl)carbamic acid ester], a KCNQ potassium channel opener, via modulation of mesolimbic dopaminergic neurotransmission.
Sotty F; Damgaard T; Montezinho LP; Mørk A; Olsen CK; Bundgaard C; Husum H
J Pharmacol Exp Ther; 2009 Mar; 328(3):951-62. PubMed ID: 19098162
[TBL] [Abstract][Full Text] [Related]
8. The pharmacological effect of positive KCNQ (Kv7) modulators on dopamine release from striatal slices.
Jensen MM; Lange SC; Thomsen MS; Hansen HH; Mikkelsen JD
Basic Clin Pharmacol Toxicol; 2011 Nov; 109(5):339-42. PubMed ID: 21599837
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of striatal cholinergic interneuron activity by the Kv7 opener retigabine and the nonsteroidal anti-inflammatory drug diclofenac.
Paz RM; Tubert C; Stahl A; Díaz AL; Etchenique R; Murer MG; Rela L
Neuropharmacology; 2018 Jul; 137():309-321. PubMed ID: 29758221
[TBL] [Abstract][Full Text] [Related]
10. Activation of voltage-gated KCNQ/Kv7 channels by anticonvulsant retigabine attenuates mechanical allodynia of inflammatory temporomandibular joint in rats.
Xu W; Wu Y; Bi Y; Tan L; Gan Y; Wang K
Mol Pain; 2010 Aug; 6():49. PubMed ID: 20796319
[TBL] [Abstract][Full Text] [Related]
11. Activation of KCNQ Channels Suppresses Spontaneous Activity in Dorsal Root Ganglion Neurons and Reduces Chronic Pain after Spinal Cord Injury.
Wu Z; Li L; Xie F; Du J; Zuo Y; Frost JA; Carlton SM; Walters ET; Yang Q
J Neurotrauma; 2017 Mar; 34(6):1260-1270. PubMed ID: 28073317
[TBL] [Abstract][Full Text] [Related]
12. Kv7 channels in the nucleus accumbens are altered by chronic drinking and are targets for reducing alcohol consumption.
McGuier NS; Griffin WC; Gass JT; Padula AE; Chesler EJ; Mulholland PJ
Addict Biol; 2016 Nov; 21(6):1097-1112. PubMed ID: 26104325
[TBL] [Abstract][Full Text] [Related]
13. Enhancing KCNQ Channel Activity Improves Neurobehavioral Recovery after Spinal Cord Injury.
Wu Z; Li L; Xie F; Xu G; Dang D; Yang Q
J Pharmacol Exp Ther; 2020 Apr; 373(1):72-80. PubMed ID: 31969383
[TBL] [Abstract][Full Text] [Related]
14. Inhibitory effects of retigabine, a Kv7 channel activator, on mechanosensitive primary bladder afferent activities and nociceptive behaviors in rats.
Aizawa N; Wakamatsu D; Kida J; Otsuki T; Saito Y; Matsuya H; Homma Y; Igawa Y
Neurourol Urodyn; 2017 Feb; 36(2):280-285. PubMed ID: 26536146
[TBL] [Abstract][Full Text] [Related]
15. Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy.
Zhang F; Liu Y; Tang F; Liang B; Chen H; Zhang H; Wang K
FASEB J; 2019 Aug; 33(8):9154-9166. PubMed ID: 31063701
[TBL] [Abstract][Full Text] [Related]
16. Restoration of Kv7 Channel-Mediated Inhibition Reduces Cued-Reinstatement of Cocaine Seeking.
Parrilla-Carrero J; Buchta WC; Goswamee P; Culver O; McKendrick G; Harlan B; Moutal A; Penrod R; Lauer A; Ramakrishnan V; Khanna R; Kalivas P; Riegel AC
J Neurosci; 2018 Apr; 38(17):4212-4229. PubMed ID: 29636392
[TBL] [Abstract][Full Text] [Related]
17. Kv7 (KCNQ) channel openers induce hypothermia in the mouse.
Kristensen LV; Sandager-Nielsen K; Hansen HH
Neurosci Lett; 2011 Jan; 488(2):178-82. PubMed ID: 21087654
[TBL] [Abstract][Full Text] [Related]
18. Expression and motor functional roles of voltage-dependent type 7 K(+) channels in the human taenia coli.
Adduci A; Martire M; Taglialatela M; Arena V; Rizzo G; Coco C; Currò D
Eur J Pharmacol; 2013 Dec; 721(1-3):12-20. PubMed ID: 24120659
[TBL] [Abstract][Full Text] [Related]
19. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
Liu H; Jia L; Chen X; Shi L; Xie J
Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
[TBL] [Abstract][Full Text] [Related]
20. Suppression of KCNQ/M (Kv7) potassium channels in the spinal cord contributes to the sensitization of dorsal horn WDR neurons and pain hypersensitivity in a rat model of bone cancer pain.
Cai J; Fang D; Liu XD; Li S; Ren J; Xing GG
Oncol Rep; 2015 Mar; 33(3):1540-50. PubMed ID: 25592230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
